Initial results of BMS-986012, a first-in-class fucosyl-GM1 mAb, in combination with nivolumab, in pts with relapsed/refractory (rel/ref) small-cell lung cancer (SCLC)-MedSci.cn

Initial results of BMS-986012, a first-in-class fucosyl-GM1 mAb, in combination with nivolumab, in pts with relapsed/refractory (rel/ref) small-cell lung cancer (SCLC)

Chu, QSC; van Herpen, C; Leighl, NB; Markman, B; Clarke, S; Juergens, RA; Basciano, P; Lathers, D; Tannenbaum-Dvir, S; Urbanska, K; Kollia, G; Darby, C; Williams, D; Kolaitis, G; Ready, N

ANNALS OF ONCOLOGY, 2017; 28 ( ):

科室
- - 订阅+
  - 更多科室
工具
服务